Bright-field In Situ Hybridization for HER2 Gene Amplification in Breast Cancer Using Tissue Microarrays Correlation Between Chromogenic (CISH) and Automated Silver-enhanced (SISH) Methods With Patient Outcome

Francis, Glenn D., Jones, Mark A., Beadle, Geoffrey F. and Stein, Sandra R. (2009) Bright-field In Situ Hybridization for HER2 Gene Amplification in Breast Cancer Using Tissue Microarrays Correlation Between Chromogenic (CISH) and Automated Silver-enhanced (SISH) Methods With Patient Outcome. Diagnostic Molecular Pathology, 18 2: 88-95. doi:10.1097/PDM.obo13e31816f6374


Author Francis, Glenn D.
Jones, Mark A.
Beadle, Geoffrey F.
Stein, Sandra R.
Title Bright-field In Situ Hybridization for HER2 Gene Amplification in Breast Cancer Using Tissue Microarrays Correlation Between Chromogenic (CISH) and Automated Silver-enhanced (SISH) Methods With Patient Outcome
Journal name Diagnostic Molecular Pathology   Check publisher's open access policy
ISSN 1052-9551
Publication date 2009-06-01
Year available 2009
Sub-type Article (original research)
DOI 10.1097/PDM.obo13e31816f6374
Open Access Status Not Open Access
Volume 18
Issue 2
Start page 88
End page 95
Total pages 8
Editor Stoler, Mark H.
Place of publication USA
Publisher Lippincott Williams & Wilkins
Language eng
Subject 920102 Cancer and Related Disorders
110316 Pathology (excl. Oral Pathology)
C1
Abstract Introduction: HER2 gene amplification or overexpression occurs in 15% to 25% of breast cancers and has implications for treatment and prognosis. The most commonly used methods for HER2 testing are fluorescence in situ hybridization (FISH) and immunohistochemistry. FISH is considered to be the reference standard and more accurately predicts response to trastuzumab, but is technically demanding, expensive, and requires specialized equipment. In situ hybridization is required to be eligible for adjuvant treatment with trastuzumab in Australia. Bright-field in situ hybridization is an alternative to FISH and uses a combination of in situ methodology and a peroxidase-mediated chromogenic substrate such as diaminobenzidine [chromogenic in situ hybridization (CISH)] or multimer technology coupled with enzyme metallography [silver-enhanced in situ hybridization (SISH)] to create a marker visible under bright-field microscopy. CISH was introduced into diagnostic testing in Australia in October 2006. SISH methodology is a more recent introduction into the testing repertoire. An evaluation of CISH and SISH performance to assess patient outcome were performed using tissue microarrays. Materials and Methods: Tissue microarrays were constructed in duplicate using material from 593 patients with invasive breast carcinoma and assessed using CISH and SISH. Gene amplification was assessed using the American Society of Clinical Oncology/College of American Pathologists guideline and Australian HER2 Advisory Board criteria (single probe: diploid, 1 to 2.5 copies/nucleus; polysomy >2.5 to 4 copies/nucleus; equivocal, >4 to 6 copies/nucleus; low-level amplification, >6 to 10 copies/nucleus and high-level amplification >10 copies/nucleus; dual probe HER2/CHR17 ratio: nonamplified <1.8, equivocal 1.8 to 2.2, amplified >2.2). Results: Results were informative for 337 tissue cores comprising 230 patient samples. Concordance rates were 96% for HER2 single probe CISH and SISH and 95.5% for single probe CISH and dual probe HER2/CHR17 SISH. Both bright-field methods correlated with immunohistochemistry results and with breast cancer-specific survival. Conclusions: HER2 SISH testing combines the advantages of automation and bright-field microscopy to facilitate workflow within the laboratory, improves turnaround time, and correlates with patient outcome.
Keyword breast cancer
ESTROGEN-RECEPTOR
Q-Index Code C1
Q-Index Status Confirmed Code

Document type: Journal Article
Sub-type: Article (original research)
Collections: 2010 Higher Education Research Data Collection
School of Public Health Publications
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 41 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 47 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 03 Sep 2009, 18:05:04 EST by Mr Andrew Martlew on behalf of Medicine - Princess Alexandra Hospital